ALNY vs KYMR · P/E 76, rev $1.29B vs rev $99.4M
Alnylam Pharmaceuticals Inc (ALNY) versus Kymera Therapeutics Inc (KYMR) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Kymera Therapeutics Inc (KYMR) is a biotechnology company listed on NASDAQ.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported KYMR revenue for 2026-06-30 was $99.4M. Net income was -$130.4M. KYMR currently screens at market cap $7.39B.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. KYMR currently screens at market cap $7.39B.
Not investment advice. Open the ALNY and KYMR stock pages for the full models.
Not investment advice.